[{"id":"ffa751f1-ed5d-4679-802a-6002b9595478","acronym":"","url":"https://clinicaltrials.gov/study/NCT02473497","created_at":"2021-01-18T11:54:26.767Z","updated_at":"2024-07-02T16:35:16.518Z","phase":"","brief_title":"Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients","source_id_and_acronym":"NCT02473497","lead_sponsor":"Pfizer","biomarkers":" ALK • MET • ROS1 • NTRK3 • ETV6","pipe":" | ","alterations":" NTRK3 fusion • ALK mutation • ETV6-NTRK3 fusion • ALK translocation","tags":["ALK • MET • ROS1 • NTRK3 • ETV6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK3 fusion • ALK mutation • ETV6-NTRK3 fusion • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-03-04"}]